iBio Inc.

iBio, Inc. is a biotechnology company. The Company focuses on commercializing its platform technologies, iBioLaunch and iBioModulator, and developing select product candidates based upon these platforms. iBioLaunch is a transformative platform technology for the development and production of biologics using transient gene expression in hydroponically grown, unmodified green plants. iBioModulator is a technology platform that is designed to improve the potency and duration of effect of both prophylactic and therapeutic vaccines produced with any recombinant expression technology, including iBioLaunch. The iBio pipeline includes products against fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products that are derived from human blood plasma. The Company developed its iBioModulator technology based on the use of a modified form of the cellulose degrading enzyme lichenase (LicKM), from Clostridium thermocellum.